Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

A comprehensive survey of the mutagenic impact of common cancer cytotoxics

Szikriszt, Bernadett, Póti, Ádám, Pipek, Orsolya, Krzystanek, Marcin, Kanu, Nnennaya, Molnár, János, Ribli, Dezső, Szeltner, Zoltán, Tusnády, Gábor E., Csabai, István, Szallasi, Zoltan, Swanton, Charles, Szüts, Dávid·2016·Genome Biology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13059-016-0963-7

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Cytotoxic treatments. a Colony survival assay of DT40 cells treated with the indicated cytotoxic drugs for 1 h (cisplatin, cyclophosphamide) or 24 h. The concentration chosen for mutagenesis assays are indicated with black arrows. b A schematic drawing of the mutagenesis assay. Genomic DNA was sequenced from the pre-treatment starting cell clone and three post-treatment cell clones. c Comparison of the cisplatin sensitivity of the starting clone (black) and clones isolated following four rounds of cisplatin treatment (red). Mean and SEM of three measurements is shown
Fig. 1 Cytotoxic treatments. a Colony survival assay of DT40 cells treated with the indicated cytotoxic drugs for 1 h (cisplatin, cyclophosphamide) or 24 h. The concentration chosen for mutagenesis assays are indicated with black arrows. b A schematic drawing of the mutagenesis assay. Genomic DNA was sequenced from the pre-treatment starting cell clone and three post-treatment cell clones. c Comparison of the cisplatin sensitivity of the starting clone (black) and clones isolated following four rounds of cisplatin treatment (red). Mean and SEM of three measurements is shownCC BY · PubMed Central
Fig. 2 Number and spectrum of treatment-induced SNVs. a The mean number of observed SNVs per genome following the described treatment regimen with the indicated drugs. Error bars indicate SEM. b Base substitution spectrum of mutations that arose from the mock treatment, as well as cisplatin and cyclophosphamide treatments. c The mean number of mutations per sample and base substitution spectrum of the indicated treatments. Significant differences from the mock treatment (p <0.05, Student’s t-test) are indicated with an asterisk. d Triplet mutation spectra of the mock, cisplatin and cyclophosphamide treatments. The middle base of each triplet, listed at the bottom, mutated as indicated at the top of the panel. The number of mutations of each type was normalised to the frequency of occurrence of that base triplet in the chicken genome, and the resulting mutation rates are shown
Fig. 2 Number and spectrum of treatment-induced SNVs. a The mean number of observed SNVs per genome following the described treatment regimen with the indicated drugs. Error bars indicate SEM. b Base substitution spectrum of mutations that arose from the mock treatment, as well as cisplatin and cyclophosphamide treatments. c The mean number of mutations per sample and base substitution spectrum of the indicated treatments. Significant differences from the mock treatment (p <0.05, Student’s t-test) are indicated with an asterisk. d Triplet mutation spectra of the mock, cisplatin and cyclophosphamide treatments. The middle base of each triplet, listed at the bottom, mutated as indicated at the top of the panel. The number of mutations of each type was normalised to the frequency of occurrence of that base triplet in the chicken genome, and the resulting mutation rates are shownCC BY · PubMed Central
Fig. 3 SNV mutation spacing, dinucleotide mutations and proposed mechanisms of mono- and dinucleotide mutations. a The distance of each SNV mutation from the previous SNV on the same chromosome is plotted against the genomic position of the mutation. Thin dashed lines indicate chromosome boundaries. Chromosomes are shown in numerical order; chromosome Z is shown last on the right. The colour of each dot illustrates the type of mutation according to the key at the bottom of the panel. Mutations with an intermutation distance of one are part of dinucleotide mutations. One sequenced clone of each is shown. b Sequence analysis of the 183 dinucleotide mutations detected following cisplatin treatment. The change in the 5’ base is shown in the rows, while the 3’ base in the columns. The equivalent mutations on the two strands are added together, e.g. GG > TT is shown as CC > AA. The most common mutation types are grouped together below the table and their sequences are indicated using the purine-rich strand to aid interpretation. c Schematic models for the replicative process that may generate each of the most common classes of cisplatin-induced mononucleotide (c) and dinucleotide (d) mutations. Putative intrastrand crosslinks are marked, the uncertain lesion at mutated GA sequences is indicated with a question mark. Non-canonical base pairing is shown with a zig-zag symbol. The contribution of each mutation class to the total number of observed SNVs is shown
Fig. 3 SNV mutation spacing, dinucleotide mutations and proposed mechanisms of mono- and dinucleotide mutations. a The distance of each SNV mutation from the previous SNV on the same chromosome is plotted against the genomic position of the mutation. Thin dashed lines indicate chromosome boundaries. Chromosomes are shown in numerical order; chromosome Z is shown last on the right. The colour of each dot illustrates the type of mutation according to the key at the bottom of the panel. Mutations with an intermutation distance of one are part of dinucleotide mutations. One sequenced clone of each is shown. b Sequence analysis of the 183 dinucleotide mutations detected following cisplatin treatment. The change in the 5’ base is shown in the rows, while the 3’ base in the columns. The equivalent mutations on the two strands are added together, e.g. GG > TT is shown as CC > AA. The most common mutation types are grouped together below the table and their sequences are indicated using the purine-rich strand to aid interpretation. c Schematic models for the replicative process that may generate each of the most common classes of cisplatin-induced mononucleotide (c) and dinucleotide (d) mutations. Putative intrastrand crosslinks are marked, the uncertain lesion at mutated GA sequences is indicated with a question mark. Non-canonical base pairing is shown with a zig-zag symbol. The contribution of each mutation class to the total number of observed SNVs is shownCC BY · PubMed Central
Fig. 4 Cisplatin-induced insertions and deletions. a The mean number of observed insertions (blue) and deletions (red) per genome following the described treatment regimen with the indicated drugs. Error bars indicate SEM. b Length distribution of cisplatin-induced insertions and deletions. c Heat map of the frequency of one-base insertions, classified according to the preceding and the following two bases as indicated. The inserted base is shown below each panel. The equivalent mutations on the two strands are added and shown as T or C insertions. d Table and heat map of the frequency of one-base deletions, classified according to the preceding and the following base as indicated. The equivalent mutations on the two strands are added and shown as T or C deletions, shown to the right. e A schematic model of the generation of the most common GGTT > GGTTT insertions during DNA replication. The incoming DNA polymerase (grey arrow) inserts adenosines opposite the thymine bases, then it inserts an extra adenosine upon encountering the cisplatin-induced GG intrastrand crosslink. f Sequence context of the most common one-base deletions shown on the purine rich strand, with the position of putative intrastrand crosslinks indicated above the sequence
Fig. 4 Cisplatin-induced insertions and deletions. a The mean number of observed insertions (blue) and deletions (red) per genome following the described treatment regimen with the indicated drugs. Error bars indicate SEM. b Length distribution of cisplatin-induced insertions and deletions. c Heat map of the frequency of one-base insertions, classified according to the preceding and the following two bases as indicated. The inserted base is shown below each panel. The equivalent mutations on the two strands are added and shown as T or C insertions. d Table and heat map of the frequency of one-base deletions, classified according to the preceding and the following base as indicated. The equivalent mutations on the two strands are added and shown as T or C deletions, shown to the right. e A schematic model of the generation of the most common GGTT > GGTTT insertions during DNA replication. The incoming DNA polymerase (grey arrow) inserts adenosines opposite the thymine bases, then it inserts an extra adenosine upon encountering the cisplatin-induced GG intrastrand crosslink. f Sequence context of the most common one-base deletions shown on the purine rich strand, with the position of putative intrastrand crosslinks indicated above the sequenceCC BY · PubMed Central
Fig. 5 Mutation density with respect to gene transcription. a The proportion of genomic regions classified as intergenic (green) or genic (red) based on Ensembl genome annotation, shown on the left, differs from the proportion of cisplatin or cyclophosphamide-induced SNVs found in the respective regions (middle and right columns). b The distribution of the expression level of all genes, based on RNA-Seq coverage data (green) is shown against the distribution of the expression level of genes containing cisplatin or cyclophosphamide-induced SNVs (red). Expression levels are shown as the log10 of FPKM values (fragments per kilobase of transcript per million of mapped reads). c Strand bias of genic mutations induced by cisplatin (left) or cyclophosphamide (right). Highly significant (p <0.001, χ2 test) differences between the non-transcribed and the transcribed strands are indicated with double asterisks
Fig. 5 Mutation density with respect to gene transcription. a The proportion of genomic regions classified as intergenic (green) or genic (red) based on Ensembl genome annotation, shown on the left, differs from the proportion of cisplatin or cyclophosphamide-induced SNVs found in the respective regions (middle and right columns). b The distribution of the expression level of all genes, based on RNA-Seq coverage data (green) is shown against the distribution of the expression level of genes containing cisplatin or cyclophosphamide-induced SNVs (red). Expression levels are shown as the log10 of FPKM values (fragments per kilobase of transcript per million of mapped reads). c Strand bias of genic mutations induced by cisplatin (left) or cyclophosphamide (right). Highly significant (p <0.001, χ2 test) differences between the non-transcribed and the transcribed strands are indicated with double asterisksCC BY · PubMed Central
Fig. 6 Correlation of drug-induced mutation patterns with mutation signatures identified in cancer. a Heat map of the Pearson correlation coefficient between triplet base mutation patterns induced by the cytotoxic treatment adjusted to human triplet frequencies (rows) and the 30 confirmed mutational signatures identified in human cancer [43]. The heat map key is shown at the bottom, with an overlaid histogram indicating the number of cells in each value range. b Heat map showing Pearson correlation coefficients between each pair of treatment-induced mutational patterns
Fig. 6 Correlation of drug-induced mutation patterns with mutation signatures identified in cancer. a Heat map of the Pearson correlation coefficient between triplet base mutation patterns induced by the cytotoxic treatment adjusted to human triplet frequencies (rows) and the 30 confirmed mutational signatures identified in human cancer [43]. The heat map key is shown at the bottom, with an overlaid histogram indicating the number of cells in each value range. b Heat map showing Pearson correlation coefficients between each pair of treatment-induced mutational patternsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 68

  1. Choi DK, Helenowski I, Hijiya N. Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer. 2014;135:1764–73. · DOI
  2. OECD Guidelines for the Testing of Chemicals, Section 4:Health Effects. OECD Publications. 2015. http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-effects_20745788 . Accessed 12 Nov 2015
  3. Kang SH, Kwon JY, Lee JK, Seo YR. Recent advances in in vivo genotoxicity testing: prediction of carcinogenic potential using comet and micronucleus assay in animal models. J Cancer Prev. 2013;18:277–88. · DOI
  4. Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res. 2000;455:29–60. · DOI · Paper page
  5. Johnson GE. Mammalian cell HPRT gene mutation assay: test methods. Methods Mol Biol. 2012;817:55–67. · doi:10.1007/978-1-61779-421-6_4
  6. Povirk LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res. 1994;318:205–26. · DOI · Paper page
  7. Pillaire MJ, Hoffmann JS, Defais M, Villani G. Replication of DNA containing cisplatin lesions and its mutagenic consequences. Biochimie. 1995;77:803–7. · doi:10.1016/0300-9084(96)88199-5
  8. Meier B, Cooke SL, Weiss J, Bailly AP, Alexandrov LB, Marshall J, et al. C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res. 2014;24:1624–36. · DOI · Paper page
  9. Pendleton M, Lindsey Jr RH, Felix CA, Grimwade D, Osheroff N. Topoisomerase II and leukemia. Ann N Y Acad Sci. 2014;1310:98–110. · DOI · Paper page
  10. Boos G, Stopper H. Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett. 2000;116:7–16. · DOI · Paper page
  11. Saintigny Y, Delacote F, Vares G, Petitot F, Lambert S, Averbeck D, et al. Characterization of homologous recombination induced by replication inhibition in mammalian cells. Embo J. 2001;20:3861–70. · DOI · Paper page
  12. Aydemir N, Celikler S, Bilaloglu R. In vitro genotoxic effects of the anticancer drug gemcitabine in human lymphocytes. Mutat Res. 2005;582:35–41. · doi:10.1016/j.mrgentox.2004.12.013
  13. Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, Selfridge J, et al. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol. 2009;7:e91. · DOI
  14. Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Regairaz M, Pommier Y, et al. Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl Acad Sci U S A. 2015;112:1571–6. · DOI · Paper page
  15. Benedict WF, Baker MS, Haroun L, Choi E, Ames BN. Mutagenicity of cancer chemotherapeutic agents in the Salmonella/microsome test. Cancer Res. 1977;37:2209–13.
  16. Nakanomyo H, Hiraoka M, Shiraya M. Mutagenicity tests of etoposide and teniposide. J Toxicol Sci. 1986;11 Suppl 1:301–10. · doi:10.2131/jts.11.supplementi_301
  17. Zounkova R, Kovalova L, Blaha L, Dott W. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere. 2010;81:253–60. · DOI
  18. Suter W, Romagna F. DNA repair induced by various mutagens in rat hepatocyte primary cultures measured in the presence of hydroxyurea, guanazole or aphidicolin. Mutat Res. 1990;231:251–64. · doi:10.1016/0027-5107(90)90031-x
  19. Vieira IL, de Souza DC, da Silva CL, Chen LC, Guillo LA. In vitro mutagenicity and blood compatibility of paclitaxel and curcumin in poly (DL-lactide-co-glicolide) films. Toxicol In Vitro. 2013;27:198–203. · doi:10.1016/j.tiv.2012.10.013
  20. Silva MJ, Costa P, Dias A, Valente M, Louro H, Boavida MG. Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells. Environ Mol Mutagen. 2005;46:104–15. · DOI
  21. Michalopoulos G, Strom SC, Kligerman AD, Irons GP, Novicki DL. Mutagenesis induced by procarcinogens at the hypoxanthine-guanine phosphoribosyl transferase locus of human fibroblasts cocultured with rat hepatocytes. Cancer Res. 1981;41:1873–8.
  22. Dickins M, Wright K, Phillips M, Todd N. Toxicity and mutagenicity tests of 4 anti-cancer drugs in cultured Chinese hamster cells. Mutat Res. 1985;143:149–54. · doi:10.1016/s0165-7992(85)80026-9
  23. Gupta RS, Bromke A, Bryant DW, Gupta R, Singh B, McCalla DR. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems. Mutagenesis. 1987;2:179–86. · doi:10.1093/mutage/2.3.179
  24. Mattano SS, Palella TD, Mitchell BS. Mutations induced at the hypoxanthine-guanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate pools. Cancer Res. 1990;50:4566–71.
  25. Nik-Zainal S, Kucab JE, Morganella S, Glodzik D, Alexandrov LB, Arlt VM, et al. The genome as a record of environmental exposure. Mutagenesis. 2015;30:763–70.
  26. Severson PL, Vrba L, Stampfer MR, Futscher BW. Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014;775–776:48–54. · DOI
  27. Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallee MP, et al. Modelling mutational landscapes of human cancers in vitro. Sci Rep. 2014;4:4482. · DOI
  28. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med. 2013;5:197ra01.
  29. Yamazoe M, Sonoda E, Hochegger H, Takeda S. Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40. DNA Repair (Amst). 2004;3:1175–85. · DOI
  30. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther. 1988;37:301–55. · DOI · Paper page
  31. Hannon-Fletcher MP, Barnett YA. Lymphocyte cytochrome P450 expression: inducibility studies in male Wistar rats. Br J Biomed Sci. 2008;65:1–6. · DOI
  32. Saurabh K, Parmar D. Evidence for cytochrome P450 2B1/2B2 isoenzymes in freshly prepared peripheral blood lymphocytes. Biomarkers. 2011;16:649–56. · doi:10.3109/1354750x.2011.622412
  33. Pipek O, Ribli D, Molnár J, Póti Á, Krzystanek M, Bodor A, et al. Accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut. http://www.genomics.hu/tools/isomut/isomut_publications.html . Accessed 3 May 2016. · DOI
  34. Pfeifer GP. Mutagenesis at methylated CpG sequences. Curr Top Microbiol Immunol. 2006;301:259–81.
  35. Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry. 1986;25:3912–5. · DOI · Paper page
  36. Lemaire MA, Schwartz A, Rahmouni AR, Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. Proc Natl Acad Sci U S A. 1991;88:1982–5. · DOI · Paper page
  37. Pillaire MJ, Margot A, Villani G, Sarasin A, Defais M, Gentil A. Mutagenesis in monkey cells of a vector containing a single d(GPG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene. Nucleic Acids Res. 1994;22:2519–24. · doi:10.1093/nar/22.13.2519
  38. Huang H, Woo J, Alley SC, Hopkins PB. DNA-DNA interstrand cross-linking by cis-diamminedichloroplatinum(II): N7(dG)-to-N7(dG) cross-linking at 5′-d(GC) in synthetic oligonucleotides. Bioorg Med Chem. 1995;3:659–69. · doi:10.1016/0968-0896(95)00059-p
  39. Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47:1402–7. · DOI · Paper page
  40. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21:7435–51. · DOI · Paper page
  41. Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci. 2011;102:663–9. · DOI
  42. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009;69:6381–6. · DOI · Paper page
  43. Molnár J, Póti A, Pipek O, Krzystanek M, Kanu N, Swanton C, et al. The genome of the chicken DT40 bursal lymphoma cell line. G3 (Bethesda). 2014;4:2231–40. · DOI
  44. Evans TJ, Yamamoto KN, Hirota K, Takeda S. Mutant cells defective in DNA repair pathways provide a sensitive high-throughput assay for genotoxicity. DNA Repair (Amst). 2010;9:1292–8. · doi:10.1016/j.dnarep.2010.09.017
  45. Zhu YO, Siegal ML, Hall DW, Petrov DA. Precise estimates of mutation rate and spectrum in yeast. Proc Natl Acad Sci U S A. 2014;111:E2310–8. · DOI · Paper page
  46. Campbell CD, Eichler EE. Properties and rates of germline mutations in humans. Trends Genet. 2013;29:575–84. · DOI · Paper page
  47. Hemminki K. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Cancer Res. 1985;45:4237–43.
  48. Gorelick NJ, Andrews JL, de Boer JG, Young R, Gibson DP, Walker VE. Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice. Environ Mol Mutagen. 1999;34:154–66. · doi:10.1002/(sici)1098-2280(1999)34:2/3<154::aid-em15>3.0.co;2-0
  49. Maccubbin AE, Caballes L, Riordan JM, Huang DH, Gurtoo HL. A cyclophosphamide/DNA phosphoester adduct formed in vitro and in vivo. Cancer Res. 1991;51:886–92.
  50. Ma B, Villalta PW, Zarth AT, Kotandeniya D, Upadhyaya P, Stepanov I, et al. Comprehensive high-resolution mass spectrometric analysis of DNA phosphate adducts formed by the tobacco-specific lung carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone. Chem Res Toxicol. 2015;28:2151–9. · DOI
  51. Hoffmann JS, Pillaire MJ, Maga G, Podust V, Hübscher U, Villani G. DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci U S A. 1995;92:5356–60. · DOI
  52. Lee YS, Gregory MT, Yang W. Human Pol ζ purified with accessory subunits is active in translesion DNA synthesis and complements Pol η in cisplatin bypass. Proc Natl Acad Sci U S A. 2014;111:2954–9. · DOI · Paper page
  53. Huang KK, Jang KW, Kim S, Kim HS, Kim SM, Kwon HJ, et al. Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Sci Rep. 2016;6:19552. · DOI
  54. Costello M, Pugh TJ, Fennell TJ, Stewart C, Lichtenstein L, Meldrim JC, et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 2013;41:e67. · DOI · Paper page
  55. Parkhomchuk D, Amstislavskiy V, Soldatov A, Ogryzko V. Use of high throughput sequencing to observe genome dynamics at a single cell level. Proc Natl Acad Sci U S A. 2009;106:20830–5. · DOI
  56. Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell. 2012;46:424–35. · DOI · Paper page
  57. Faust GG, Hall IM. SAMBLASTER: fast duplicate marking and structural variant read extraction. Bioinformatics. 2014;30:2503–5. · DOI · Paper page
  58. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303. · DOI · Paper page
  59. Wang J, Mullighan CG, Easton J, Roberts S, Heatley SL, Ma J, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods. 2011;8:652–4. · DOI · Paper page
  60. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105–11. · DOI · Paper page
  61. Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol. 2004;57:756–63. · DOI
  62. Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res. 1987;47:2723–6.
  63. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998;91:1533–41. · DOI
  64. Masumori N, Kunishima Y, Hirobe M, Takeuchi M, Takayanagi A, Tsukamoto T, et al. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. Jpn J Clin Oncol. 2008;38:182–5. · doi:10.1093/jjco/hym171
  65. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988;48:1676–9.
  66. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 1984;44:379–82.
  67. Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci. 2010;41:458–63. · DOI · Paper page
  68. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454–7.

Cited by

See all 181

Metadata

Authors
Szikriszt, B., Póti, Á., Pipek, O., Krzystanek, M., Kanu, N., Molnár, J., Ribli, D., Szeltner, Z., Tusnády, G. E., Csabai, I., Szallasi, Z., Swanton, C., & Szüts, D.
Venue
Genome Biology
Published
2016-05-09
Volume
17
Issue
1
ISSN
1474-760X
Cited by
181
References
7
Language
en
Funders
  • Magyar Tudományos Akadémia (HU) (Momentum Grant LP2011-015)
  • Magyar Tudományos Akadémia (Momentum Grant LP2012)
  • Országos Tudományos Kutatási Alapprogramok (K104586)
  • Seventh Framework Programme (PREDICT, RESPONSIFY, ID:259303)
  • Rosetrees Trust
  • Cancer Research UK
  • Prostate Cancer Foundation
  • Breast Cancer Research Foundation
  • European Research Council
  • Basser Foundation
  • Széchenyi Program (HU) (KTIA_NAP_13-2014-0021)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comprehensive survey of the mutagenic impact of common cancer cytotoxics. https://app.cochat.ai/papers/10.1186/s13059-016-0963-7
The paper
Szikriszt, B., Póti, Á., Pipek, O., Krzystanek, M., Kanu, N., Molnár, J., Ribli, D., Szeltner, Z., Tusnády, G. E., Csabai, I., Szallasi, Z., Swanton, C., & Szüts, D. (2016). A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biology. https://doi.org/10.1186/s13059-016-0963-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.